Long-term follow-up of endurance and safety outcomes during enzyme replacement therapy for mucopolysaccharidosis VI: Final results of three clinical studies of recombinant human N-acetylgalactosamine 4-sulfatase

Simple item page
dc.contributor.authorHarmatz, P.
dc.contributor.authorGiugliani, R.
dc.contributor.authorSchwartz, I.
dc.contributor.authorGuffon, N.
dc.contributor.authorTeles, E.
dc.contributor.authorMiranda, C.
dc.contributor.authorWraith, J.
dc.contributor.authorBeck, M.
dc.contributor.authorArash, L.
dc.contributor.authorScarpa, M.
dc.contributor.authorKetteridge, D.
dc.contributor.authorHopwood, J.
dc.contributor.authorPlecko, B.
dc.contributor.authorSteiner, R.
dc.contributor.authorWhitley, C.
dc.contributor.authorKaplan, P.
dc.contributor.authorYu, Z.
dc.contributor.authorSwiedler, S.
dc.contributor.authorDecker, C.
dc.date.issued2008
dc.descriptionCopyright © 2008 Elsevier Inc. All rights reserved.
dc.description.abstract<h4>Unlabelled</h4>The objective of this study was to evaluate the long-term clinical benefits and safety of recombinant human arylsulfatase B (rhASB) treatment of mucopolysaccharidosis type VI (MPS VI: Maroteaux-Lamy syndrome), a lysosomal storage disease. Fifty-six patients derived from 3 clinical studies were followed in open-label extension studies for a total period of 97-260 Weeks. All patients received weekly infusions of rhASB at 1 mg/kg. Efficacy was evaluated by (1) distance walked in a 12-minute walk test (12MWT) or 6-minute walk test (6MWT), (2) stairs climbed in the 3-minute stair climb (3MSC), and (3) reduction in urinary glycosaminoglycans (GAG). Safety was evaluated by compliance, adverse event (AE) reporting and adherence to treatment.<h4>Results</h4>A significant reduction in urinary GAG (71-79%) was sustained. For the 12MWT, subjects in Phase 2 showed improvement of 255+/-191 m (mean+/-SD) at Week 144; those in Phase 3 Extension demonstrated improvement from study baseline of 183+/-26 m (mean+/- SE) in the rhASB/rhASB group at Week 96 and from treatment baseline (Week 24) of 117+/-25 m in the placebo/rhASB group. The Phase 1/2 6MWT and the 3MSC from Phase 2 and 3 also showed sustained improvements through the final study measurements. Compliance was 98% overall. Only 560 of 4121 reported AEs (14%) were related to treatment with only 10 of 560 (2%) described as severe.<h4>Conclusion</h4>rhASB treatment up to 5 years results in sustained improvements in endurance and has an acceptable safety profile.
dc.description.statementofresponsibilityPaul Harmatz, Roberto Giugliani, Ida Vanessa D. Schwartz, Nathalie Guffon, Elisa Leão Teles, M. Clara Sá Miranda, J. Edmond Wraith, Michael Beck, Laila Arash, Maurizio Scarpa, David Ketteridge, John J. Hopwood, Barbara Plecko, Robert Steiner, Chester B. Whitley, Paige Kaplan, Zi-Fan Yu, Stuart J. Swiedler, Celeste Decker and for the MPS VI Study Group
dc.description.urihttp://www.elsevier.com/wps/find/journaldescription.cws_home/622920/description#description
dc.identifier.citationMolecular Genetics and Metabolism, 2008; 94(4):469-475
dc.identifier.doi10.1016/j.ymgme.2008.04.001
dc.identifier.issn1096-7192
dc.identifier.issn1096-7206
dc.identifier.urihttp://hdl.handle.net/2440/52128
dc.language.isoen
dc.publisherAcademic Press Inc Elsevier Science
dc.source.urihttps://doi.org/10.1016/j.ymgme.2008.04.001
dc.subjectMPS VI Study Group
dc.subjectHumans
dc.subjectMucopolysaccharidosis VI
dc.subjectN-Acetylgalactosamine-4-Sulfatase
dc.subjectGlycosaminoglycans
dc.subjectRecombinant Proteins
dc.subjectTreatment Outcome
dc.subjectWalking
dc.subjectFollow-Up Studies
dc.subjectMotor Activity
dc.subjectAdolescent
dc.subjectAdult
dc.subjectChild
dc.subjectChild, Preschool
dc.subjectFemale
dc.subjectMale
dc.titleLong-term follow-up of endurance and safety outcomes during enzyme replacement therapy for mucopolysaccharidosis VI: Final results of three clinical studies of recombinant human N-acetylgalactosamine 4-sulfatase
dc.typeJournal article
pubs.publication-statusPublished

Files

Collections

Paediatrics publications